|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Collaboration for success:the value of strategic collaborations for precision medicine and biomarker discovery显示文摘Precision medicine aims to provide the precise treatment for the patient with the right dose at the right point of time.Biomarkers(BM)are vital for the identification of patients who would benefit the most from individualized treatment.In addition,they help to enable the prediction of prognosis,the detection of early therapeutic and adverse effects,and may serve as surrogate endpoints in clinical trials.BM are becoming essential tools to increase productivity in drug discovery and impressively enhance the way medicine is practiced.However,the identification,sufficient validation and implementation of such BM are challenging.This process requires expertise from different areas and high resource investments.Collaborations of different partners may be helpful to overcome these challenges.In the past decade,collaborations between diagnostics and pharmaceutical companies as well as industrial–academic collaborations have been increasingly pursued.Moreover,public funding may offer support and open new opportunities to form such consortia.Herein we give an overview of the different types of collaborations,their opportunities and challenges,and describe experiences in forming strategic partnerships with other companies. | Lilla Landeck Monika Lessl Joachim Reischl Andreas Busch Patricia Carrigan Matthias Gottwald Petra Reinke Khusru Asadullah | 2016 | Advances in Precision Medicine2016，1，1： | 3 |
| 2 | IL-22 Increases the Innate Immunity of Tissues显示文摘 | Kerstin Wolk Stefanie Kunz Ellen Witte Markus Friedrich Khusru Asadullah Robert Sabat | 2004 | Immunity2004，，2： | 1 |
| 3 | IL-22 Increases the Innate Immunity of Tissues显示文摘 | Kerstin Wolk Stefanie Kunz Ellen Witte Markus Friedrich Khusru Asadullah Robert Sabat | 2004 | Immunity2004，，2： | 1 |
| 4 | Cutting edge:immune cells as sources and targets of the IL-10 family members?显示文摘 | Kerstin Wolk Stefanie Kunz Khusru Asadullah | | 0，，： | 1 |
| 5 | Influence of monomethylfumarate on monocytic cytokine formation-explanation for adverse and therapeutic effects in psoriasis显示文摘 | Holger Schmid Markus Friedrich | 1997 | Arch Dermatol Res1997，289，： | 1 |
| 6 | Immune cells as source and targets of IL- 10 family members显示文摘 | Wolk K Kunz S Khusru A | 2002 | J Immunology2002，168，： | 1 |
| 7 | Immunopathogenesis of psoriasis显示文摘 | Robert Sabat Sandra Philipp Conny Hoflich Stefanic Kreutzer Elizabeth Wallace Khusru Asadullah Hans-Dieter Volk Wolfram Sterry and Kerstin Wolk | 2007 | Experimental Dermatology2007，16，： | 1 |
| 8 | Advances in precision medicine—time for a new journal显示文摘On January 20,2015,President Barack Obama announced a major research initiative,“Tonight,I am launching a new personalized medicine initiative to bring us closer to curing diseases like cancer and diabetes and to give all of us access to the personalized information we need to keep ourselves and our families healthier”.[1]The announcement itself indicates commitment and high expectations.Indeed personalized or precision medicine(PM)is presently considered to represent one of the most important trends in medicine.It may be regarded as another milestone in the‘evolution’of medicine beginning from the theory of ancient humoralism.This dominated medicine and science over a period or several thousands of years until the mid-nineteenth century when it was replaced by the introduction of modern cellular pathology.Further essential milestones on the way to PM are the discovery of the DNA by Watson and Crick in 1953 and the Human Genome Project determining to sequence the DNA that was completed in 2003[2]. | Lilla Landeck Robert L Holland Khusru Asadullah | 2016 | Advances in Precision Medicine2016，1，1： | 1 |
| 9 | Mechanisms involved in the side effects of glucocorticoids显示文摘 | Heike Sch?cke Wolf-Dietrich D?cke Khusru Asadullah | 2002 | Pharmacology and Therapeutics2002，，1： | 1 |
| 10 | Interleukin-10 Promoter Polymorphism in Psoriasis显示文摘 | Khusru Asadullah Joyceee Eskdale Anja Wiese | 2001 | The Journal of Investigative Dermatology2001，116，6： | 1 |
| 11 | Mechanisms involved in the side effects of glucocorticoids显示文摘 | Heike Sch?cke Wolf-Dietrich D?cke Khusru Asadullah | 2002 | Pharmacology and Therapeutics2002，，1： | 1 |
| 12 | Cutting Edge: Immunue cells as sources and targets of IL-10 family members? 显示文摘 | Wolk K Kunz S Khusru A | 2002 | J Immunol2002，168，： | 1 |
| 13 | Precision medicine: do not neglect the hurdles显示文摘Tremendous expectations have been connected with precision medicine in the past years. Beside the advantages that this type of therapy offers we should be aware of its challenges too. In this issue we will highlight on specific challenges that the pharmacological industry is opposed with when developing new targeted therapies. In addition, we will discuss issues with the reproducibility of published scientific data. | Lilla Landeck Patricia Carrigan Khusru Asadullah | 2016 | Advances in Precision Medicine2016，1，2： | 0 |
| 14 | The role of open innovation in biomarker discovery显示文摘Precision medicine aims to treat diseases with special consideration for the individual biological variability. Novel biomarkers (BM) are needed to predict therapeutic responses and to allow for the selection of suitable patients for treatment with certain drugs. However, the identification and validation of appropriate BMs is challenging. Close collaboration between different partners seems to be a key success factor. While the importance of partnerships and larger, well-established consortia in BM discovery such as the pharmaceutical industry and academic institutions is well understood and has been investigated in the past, the use of open-innovation models, also known as ‘crowd sourcing for biomarkers’, is still in its infancy. Crowd sourcing comprises of a — usually via internet — request for problem solution to an open group of users in a kind of an ‘open call’. The community (crowd) is asked to provide solutions. Since the application of the crowd sourcing method offers the possibility to collect as many as possible novel ideas from a broad community with different expertise, this approach is particularly promising for BM development. In this article we describe the first examples of open-innovation models, such as the ‘grants for targets’(G4T) and biomarkers initiative ‘InnoCentive’(innovation/incentive) platform. They may be a fruitful basis for collaborative BM development in the future. | Lilla Landeck Monika Lessl Andreas Busch Matthias Gottwald Khusru Asadullah | 2016 | Advances in Precision Medicine2016，1，2： | 0 |
| 15 | Identifying the active pharmaceutical ingredient from a mixture of fumaric acid esters for the treatment of psoriasis: Hints from in vitro investigations显示文摘A mixture of fumaric acid esters (FAEs) is approved for the oral therapy of psoriasis. However, for a long time the active ingredient of this mixture was unknown. We reviewed the in vitro data available for the different FAEs present in the multi compound drug and elaborate how they may contribute to possible clinical effects. Although helpful overall, many in vitro data must be viewed critically because the concentrations used in the experiments exceed the plasma levels reached in patients. The data suggest that dimethylfumarate (DMF) is the most active compound, mediating the major therapeutic effect after metabolization into monomethylfumarate (MMF) via an according receptor expressed on target cells. Identifying the active pharmaceutical ingredient within a mixture of compounds helps to subsequently eliminate unnecessary, potentially harmful compounds. This provides a promising example for an alternative precision medicine approach in clinical practice. | Lilla Landeck Adriana Amasuno Ignasi Pau-Charles Khusru Asadullah | 2017 | Advances in Precision Medicine2017，2，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员